Live Breaking News & Updates on Premier educational event focused

Stay informed with the latest breaking news from Premier educational event focused on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Premier educational event focused and stay connected to the pulse of your community

Scramble for specialty syringes as Pfizer, feds look to extract 6th vaccine doses

Jan 28, 2021 10:36am
Pfizer and BioNTech's COVID-19 vaccine vials contain an extra doses of the in-demand shot, but those doses can only be accessed with a special needle.(Kunal Mahto/iStock/Getty Images Plus/Getty Images)
Syringe makers are scrambling to meet demand for so-called low dead space syringes as Pfizer and the U.S. look to squeeze out extra vaccine doses. The specialty needles are needed to eke out a sixth shot in Pfizer and BioNTech's Comirnaty prepared five-dose glass vials.
Physicians and pharmacists discovered the potential extra dose after they began vaccinating patients. But initial enthusiasm has been dampened by the requirement of the now-scarce specialty needles to extract the last bit from each vial.

Washington , District-of-columbia , United-states , United-kingdom , British , Biontech-comirnaty , Sam-buffone , Joe-biden , Pfizer , Washington-post , Becton-dickinson , Mckesson

Pfizer and Moderna haven't proven their COVID-19 vaccines shield against new variants: analysts

Jan 28, 2021 10:52am
One infectious disease specialist said efforts to determine if existing vaccines will work against new COVID strains have left us "in a state of ignorance" due to incomplete data.(Bill Oxford/Getty Images)
Just as the U.S. government is starting to ramp up purchases of Pfizer’s and Moderna’s mRNA vaccines to prevent COVID-19, a troubling question is emerging in the scientific community: Can these shots protect people against aggressive new variants racing through the U.K., South Africa and Brazil?
Several analysts have scoured the medical literature and interviewed infectious disease experts in an effort to answer that question. Their conclusion? There is no clear answer. At least not yet.

South-africa , Brazil , South-african , Leerink-porges , Geoffrey-porges , Joe-biden , Pfizer , Clinical-trials-summit , Premier-educational-event-focused , Decentralized-clinical , Umer-raffat , President-joe-biden

Order up: U.S. calls on Pfizer, Moderna for 200M more vaccine doses

Can Pfizer and Moderna deliver an additional 200 million COVID-19 vaccine doses to the U.S. by this summer? That's what President Joe Biden said he wants the companies to do as the administration works to bulk up vaccine supplies and dramatically speed up nationwide immunizations.

South-africa , Canada , Michigan , United-states , Belgium , Joe-biden , Pfizer , Clinical-trials-summit , Premier-educational-event-focused , Decentralized-clinical , President-biden , Biontech

Ultragenyx earns 2 rare disease drug approvals—and a validated commercial strategy

Jan 29, 2021 9:45am
Ultragenyx nabbed its third and fourth FDA approvals in 2020 and pushed through the pandemic by reaching out to patients directly. (Ultragenyx)
Rare disease pharma companies spend a lot of time looking for patients and investing in keeping them on their meds.
But what happens during a pandemic lockdown? At Ultragenyx, patient support teams kicked into high gear, making thousands of proactive outbound calls to find out what patients needed to continue their treatment.
It had just nabbed a second approval for FGF23 hormone blocker Crysvita in June 2020 for tumor-induced osteomalacia. The first nod for the drug, developed by Ultragenyx and partner Kyowa Kirin, came in April 2018 for X-linked hypophosphatemia.

Ultragenyx-crysvita , Erik-harris , Piper-sandler , Kyowa-kirin , Clinical-trials-summit , Premier-educational-event-focused , Decentralized-clinical , Commercial-officer-erik-harris , ஏறிக்-ஹாரிஸ் , பைபர்-சாண்ட்லர் , கியோவா-கிரீன்

Lilly amps Type 1 diabetes partnerships to reach more young people

Jan 28, 2021 10:30am
Eli Lilly is expanding its global Type 1 diabetes efforts to provide insulin supplies and education to young people. (Eli Lilly)
Eli Lilly is renewing and expanding a longtime Type 1 diabetes partnership to support more than six times as many children in the next 10 years.
Working with Life for a Child, Lilly plans to expand care to 150,000 young people with diabetes over the next decade, up from 23,000 last year. The global initiative provides free immediate care with medicine and equipment like reusable pens and monitors, but also longer-term education and support in living with the chronic illness.
As part of the new push, Life for a Child is joining with diabetes non-profit and advocacy group Beyond Type 1. That well-known group's four co-founders include Jonas Brothers singer Nick Jonas and "Top Chef" alum Sam Talbot from the Bravo TV series. The group claims to be the largest diabetes online organization with a myriad of efforts that fund everything from political lobbying and education programs to research for cures and assistance with medical supplies.

Tanzania , India , Pakistan , Ethiopia , Bolivia , Mike-mason , Sam-talbot , Eli-lilly , Nick-jonas , Medtronic , Beyond-type , Top-chef-sam-talbot

Roche taps into quantum computing software for Alzheimer's disease research

(Getty Images)
Alzheimer’s disease has proven to be stubbornly difficult to unravel, but Roche aims to tap into a new tool that promises to accelerate the process: the quantum computer.
Through a multi-year partnership with the U.K.’s Cambridge Quantum Computing, the Swiss drugmaker’s task force plans to explore the nascent technology’s potential for designing and delivering new therapeutic compounds.
The partnership follows a similar endeavor launched earlier this year between Google and Boehringer Ingelheim, which plans to staff its own quantum laboratory as part of the Big Pharma’s digital transformation. Google has also been developing its own quantum hardware, in the Sycamore processor, which it says has outperformed so-called “classical” supercomputers.

Cambridge , Cambridgeshire , United-kingdom , Switzerland , Swiss , Ilyas-khan , Google , Honeywell , Talipot-holdings , Ibm , Boehringer-ingelheim , Quantum-computing

Sanofi joins fellow French firms in venture to boost digital health solutions

Sanofi is pooling digital resources, know-how and capital in a new joint venture to drive healthcare solutions. The French pharma is joining tech firm Capgemini, insurance company Generali France and telecom provider Orange—all fellow French companies—with plans to advance healthcare innovation in Europe.

Paris , France-general , France , French , Paul-hudson , Capgemini , Clinical-trials-summit , Premier-educational-event-focused , Decentralized-clinical , Sanofi , Digital-marketing , Digital-health

Fierce Pharma Politics—Could a Senate drug pricing bill be 'a positive' for pharma? One analyst says so

Amid the COVID-19 pandemic, drug pricing talk has been mostly muted in Washington. But following the wins for Democrats in recent elections, analysts with Bernstein see the issue gaining steam over the next few months. In Congress, legislative efforts will likely start with the Senate Finance Committee pricing bill, which could be seen as a positive for the industry.

Washington , United-states , Joe-biden , Ronny-gal , Institute-for-clinical , Senate-finance-committee , Fierce-pharma , Clinical-trials-summit , Premier-educational-event-focused , Decentralized-clinical , Economic-review , President-joe-biden

Sanofi, after R&D setback, lends a hand to vaccine rival Pfizer for coronavirus shot production

Following its midstage coronavirus R&D setback, vaccine giant Sanofi is still looking for ways to help in the world’s effort to beat back the pandemic. It’s teaming up with leading vaccine players Pfizer and BioNTech to produce 100 million doses of the rival vaccine—even as Sanofi works to push its own programs through clinical testing.

Germany , France , French , Paul-hudson , Le-figaro , Pfizer , Glaxosmithkline , Astrazeneca , Clinical-trials-summit , Premier-educational-event-focused , Decentralized-clinical , Sanofi

AstraZeneca, BenevolentAI home in on computer-generated target for chronic kidney disease drugs

Jan 27, 2021 11:08am
BenevolentAI’s models work to predict the potential opportunities for drugs that may be overlooked, by identifying the differences in proteins expressed by healthy and diseased cells. (jlcampbell104/CC BY 2.0)
After launching a collaboration nearly two years ago to bring artificial intelligence to kidney drug design, AstraZeneca and BenevolentAI believe they’ve discovered a winner.
Using its biomedical datasets, BenevolentAI’s machine learning platform predicted the existence of a novel target in the underlying cellular mechanisms that cause chronic kidney disease—which was later confirmed through experiments by AstraZeneca researchers.
The AI-generated target has been selected by the drugmaker as a new goal for its portfolio, making it the first product to come out of the companies’ partnership, which also focuses on idiopathic pulmonary fibrosis.

Eli-lilly , Pernille-laerkegaard-hansen , Astrazeneca , Clinical-trials-summit , Premier-educational-event-focused , Decentralized-clinical , New-england-journal , எலி-லில்லி , மருத்துவ-சோதனைகள்-உச்சிமாநாடு , ப்ரிமியர்-கல்வி-நிகழ்வு-கவனம் , புதியது-இங்கிலாந்து-இதழ் ,